Lunai Bioworks shares rise 17.59% intraday after achieving complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models.

Lunai Bioworks Inc. surged 17.59% intraday after announcing a breakthrough in preclinical humanized models, with complete regression of both primary and metastatic pancreatic tumors. The achievement, a significant milestone for a biotech firm targeting oncology therapies, likely attracted investor optimism regarding the company’s pipeline potential and future revenue prospects. The development underscores progress in innovative cancer treatments, aligning with heightened market interest in therapeutic advancements.